Naloxegol
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid Induced Constipation
Conditions
Opioid Induced Constipation
Trial Timeline
Aug 16, 2018 → Mar 5, 2020
NCT ID
NCT03638440About Naloxegol
Naloxegol is a pre-clinical stage product being developed by Kyowa Kirin for Opioid Induced Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT03638440. Target conditions include Opioid Induced Constipation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03638440 | Pre-clinical | Completed |
| NCT04173858 | Pre-clinical | Completed |
| NCT02813148 | Pre-clinical | Completed |
| NCT02099591 | Phase 1 | Completed |
Competing Products
20 competing products in Opioid Induced Constipation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| ASP8082 + morphine + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP8062 + Placebo ASP8062 + buprenorphine/naloxone | Astellas Pharma | Phase 1 | 33 |
| ASP8062 + Placebo ASP8062 + buprenorphine/naloxone | Astellas Pharma | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Phase 2 | 52 |
| naloxegol + non-PAMORA laxative | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| Brenipatide + Placebo + Buprenorphine | Eli Lilly | Phase 2 | 52 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Naloxegol | AstraZeneca | Phase 1 | 33 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| Polyethylene Glycol 3350 + Movantik | AstraZeneca | Approved | 85 |